The U.S. market for diabetes diagnosis, treatment and drug delivery is
expected to exceed $17.87 billion by 2018.
The market segments covered in this report include:
traditional blood glucose meters,
continuous glucose monitoring systems,
blood glucose test strips,
lancets and lancing devices,
insulin,
insulin syringes,
insulin pens and
insulin pumps
Market growth is expected to be fueled by an increasing number of diabetics
and improved education regarding the importance of blood glucose management.
Factors such as high obesity rates, poor diet and lack of exercise will
contribute to the growing type 2 diabetic population.
Market growth for diabetes diagnosis, treatment and drug delivery will be led
by double-digit growth in the continuous glucose monitor, insulin pen and
insulin pump segments.
Within the diabetes diagnosis, treatment and drug deliver market, companies
such as Novo Nordisk, Sanofi, Eli Lilly and Lifescan lead the market, among
many others. This report provides a comprehensive and detailed analysis of
market revenues by device type, market forecasts through 2018, unit sales,
average selling prices, market drivers and limiters and a detailed competitive
analysis, including manufacturer market shares and product portfolios.
Table of Contents
Table of Contents
TABLE OF CONTENTS
LIST OF FIGURES
LIST OF CHARTS
EXECUTIVE SUMMARY
1.1. U.S. DIABETES DIAGNOSIS, TREATMENT AND DRUG DELIVERY MARKET
1.2. GROWTH TRENDS BY SEGMENT
1.3. BLOOD GLUCOSE MONITORING MARKET
1.4. INSULIN MARKET
1.5. INSULIN SYRINGE MARKET
1.6. INSULIN PEN MARKET
1.7. INSULIN PUMP MARKET
1.8. COMPETITIVE ANALYSIS
RESEARCH METHODOLOGY
2.1. RESEARCH SCOPE
2.2. IDATA'S 9-STEP METHODOLOGY
Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation for Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecast and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring
U.S. DIABETES DIAGNOSIS, TREATEMENT AND DRUG DELIVERY MARKET
3.1. INTRODUCTION
3.1.1. Types of Diabetes
3.1.1.1. Type 1 Diabetes
3.1.1.2. Type 2 Diabetes
3.1.1.3. Gestational Diabetes
3.1.1.4. Prediabetes
3.1.2. Diabetes Complications
3.1.3. Risk Factors Associated with Type I and Type 2 Diabetes
3.1.4. Signs and Symptoms
3.1.5. Diabetes Monitoring
3.1.5.1. Initial Diagnosis
3.1.5.2. Blood Glucose Monitoring Systems
3.1.5.3. Urinary Glucose Monitoring
3.1.5.4. Noninvasive and Minimally Invasive Monitoring Devices
6.3.1. Professional Blood Glucose Test Strip Market
6.3.2. Personal Blood Glucose Test Strip Market
6.4. MARKET DRIVERS AND LIMITERS
6.4.1. Market Drivers
6.4.2. Market Limiters
6.5. COMPETITIVE ANALYSIS
LANCET AND LANCING DEVICE MARKET
7.1. INTRODUCTION
7.2. MARKET OVERVIEW
7.3. MARKET ANALYSIS AND FORECAST
7.3.1. Professional Lancet and Lancing Device Market
7.3.2. Personal Lancet and Lancing Device Market
7.4. MARKET DRIVERS AND LIMITERS
7.4.1. Market Drivers
7.4.2. Market Limiters
7.5. COMPETITIVE ANALYSIS
INSULIN MARKET
8.1. INTRODUCTION
8.1.1. Insulin Types
8.2. MARKET OVERVIEW
8.3. MARKET ANALYSIS AND FORECAST
8.4. MARKET DRIVERS AND LIMITERS
8.4.1. Market Drivers
8.4.2. Market Limiters
8.5. COMPETITIVE ANALYSIS
INSULIN SYRINGE MARKET
9.1. INTRODUCTION
9.2. MARKET OVERVIEW
9.3. MARKET ANALYSIS AND FORECAST
9.3.1. Professional Insulin Syringe Market
9.3.2. Personal Insulin Syringe Market
9.4. MARKET DRIVERS AND LIMITERS
9.4.1. Market Drivers
9.4.2. Market Limiters
9.5. COMPETITIVE ANALYSIS
INSULIN PEN MARKET
10.1. INTRODUCTION
10.2. MARKET ANALYSIS AND FORECAST
10.3. MARKET DRIVERS AND LIMITERS
10.3.1. Market Drivers
10.3.2. Market Limiters
10.4. COMPETITIVE ANALYSIS
INSULIN PUMP MARKET
11.1. INTRODUCTION
11.2. MARKET OVERVIEW
11.3. MARKET ANALYSIS AND FORECAST
11.3.1. Total Traditional Insulin Pump Market
11.3.1.1. Traditional Pump Market
11.3.1.2. Infusion Set Market
11.3.2. Total Patch Pump Market
11.3.2.1. Patch Pump Controller Market
11.3.2.2. Insulin Pod Market
11.3.3. Simple Pump Market
11.4. MARKET DRIVERS AND LIMITERS
11.4.1. Market Drivers
11.4.2. Market Limiters
11.5. COMPETITIVE ANALYSIS
11.5.1.1. Emerging Competitors
APPENDIX 1: EMERGING MARKETS & ALTERNATIVE THERAPIES
12.1. ARTIFICIAL PANCREAS
12.1.1. Mechanical Artificial Pancreas
12.1.2. Bio-Artificial Pancreas
12.2. NEEDLESS INJECTORS
ABBREVIATIONS
U.S. Market for Diabetes Monitoring, Treatment and Drug Delivery 2012 published by iData Research Inc. in May 1, 2012. This report consists of 270 Pages and the price starts from US $ 6995.
The contents of this page may be different from the latest version. Please contact us for details.
Press Release
U.S. Diabetes Diagnosis and Treatment Market to Surpass $17 Billion by 2018, Double-Digit Growth in Continuous Glucose Monitor, Insulin Pen and Insulin Pump Segments
May 14th, 2012
Global Information Inc. would like to present a new market research report, "U.S. Market for Diabetes Monitoring, Treatment and Drug Delivery 2012" by iData Research Inc..
U.S. Diabetes Diagnosis and Treatment Market to Surpass $17 Billion by 2018, Double-Digit Growth in Continuous Glucose Monitor, Insulin Pen and Insulin Pump Segments
Growth in the diabetes diagnosis, treatment and drug delivery market is expected to be fueled by a rising number of diabetics and improved education and awareness surrounding the importance of blood glucose management. Led by Novo Nordisk, Sanofi, Eli Lilly and Lifescan, the U.S. market for diabetes diagnosis, treatment and drug delivery is expected to surpass $17 billion by 2018. According to the iDatas new report, double-digit growth in the continuous glucose monitor, insulin pen and insulin pump segments will lead growth in the market.
This report provides detailed analysis of market revenues by device type, market forecasts through 2018, unit sales, average selling prices, market drivers and limitations and a detailed competitive analysis. Manufacturer market shares and product portfolios are also included.
The report covers eight segments in the diabetes diagnosis, treatment and drug delivery market, including:
